{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:15:30Z","timestamp":1791944130712,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.disamonth.2026.102099","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:40:24Z","timestamp":1773952824000},"page":"102099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"given":"Sneha Annie","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanesh","family":"Ayyalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Bimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Yehya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.disamonth.2026.102099_bib0001","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF investigators and committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.disamonth.2026.102099_bib0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.disamonth.2026.102099_bib0003","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"FINEARTS-HF committees and investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2026.102099_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct Obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.disamonth.2026.102099_bib0005","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/ejhf.2337","article-title":"Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure","volume":"23","author":"Pugliese","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.disamonth.2026.102099_bib0006","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.disamonth.2026.102099_bib0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"SUMMIT trial study group. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.disamonth.2026.102099_bib0008","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"STEP-HFpEF DM Trial committees and investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.disamonth.2026.102099_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102665","article-title":"Semaglutide in HFpEF and obesity: targeting both for functional gains","volume":"13","author":"Carbone","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.disamonth.2026.102099_bib0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"SUMMIT trial Study group. Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102099_bib0011","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"10.1016\/j.disamonth.2026.102099_bib0012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.disamonth.2026.102099_bib0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol Bull"},{"key":"10.1016\/j.disamonth.2026.102099_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"10.1016\/j.disamonth.2026.102099_bib0015","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102099_bib0016","series-title":"Version 5.4. The Cochrane Collaboration","year":"2020"},{"issue":"11","key":"10.1016\/j.disamonth.2026.102099_bib0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.disamonth.2026.102099_bib0018","article-title":"Chapter 14: completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence [last updated May 2025]","author":"Sch\u00fcnemann","year":"2024","journal-title":"Cochrane Handb System Rev Intervent"},{"key":"10.1016\/j.disamonth.2026.102099_bib0019","doi-asserted-by":"crossref","unstructured":"Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025 Mar 11;151(10):656\u2013668. doi: 10.1161\/CIRCULATIONAHA.124.072679.","DOI":"10.1161\/CIRCULATIONAHA.124.072679"},{"key":"10.1016\/j.disamonth.2026.102099_bib0020","article-title":"Comparative outcomes of tirzepatide and semaglutide in patients with heart failure with preserved ejection fraction and type 2 diabetes","author":"Kishimori","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.disamonth.2026.102099_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.disamonth.2026.102099_bib0022","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","article-title":"Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.disamonth.2026.102099_bib0023","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.disamonth.2026.102099_bib0024","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.disamonth.2026.102099_bib0025","series-title":"StatPearls [Internet]","article-title":"Tirzepatide. 2024 Feb 20","author":"Farzam","year":"2025"},{"issue":"10","key":"10.1016\/j.disamonth.2026.102099_bib0026","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.disamonth.2026.102099_bib0027","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.disamonth.2026.102099_bib0028","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","article-title":"Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging","volume":"18","author":"Ng","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"10.1016\/j.disamonth.2026.102099_bib0029","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"STEP-HFpEF trial committees and investigators. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"10456","key":"10.1016\/j.disamonth.2026.102099_bib0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.disamonth.2026.102099_bib0031","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40256-025-00721-4","article-title":"Cardiovascular effects of semaglutide in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"25","author":"Sobral","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.disamonth.2026.102099_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000925","article-title":"Semaglutide in patients with obesity and heart failure irrespective of their baseline ejection fraction: an efficacy and safety meta-analysis of randomized controlled trials","author":"Otmani","year":"2025","journal-title":"Cardiol Rev"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:16:31Z","timestamp":1777104991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502926000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0011502926000374"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102099","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102099"}}